Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
PEG-PE/clay composite carriers for doxorubicin: Effect of composite structure on release, cell interaction and cytotoxicity
Tags: acute lymphocytic leukemia, Adriamycin®, cancer, chemotherapy, Doxil®, Lipodox®, lymphoma, sarcoma
BASi Method Number SAP.1193
Sign up and you’ll receive the latest updates that matter to you, delivered straight to your inbox.
